SCHEMBL4040176

SCHEMBL4040176

COc1ccc(C(=O)NC(CC(C)C)C(=O)N2CCC3C2C(=O)CN3S(=O)(=O)C(=O)c2cccnc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 7/20 0.52
CTSS P25774 2/20 0.40
ALDH1A1 P00352 2/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
PREP P48147 2/20 0.38
FAP Q12884 1/20 0.38
LMNA P02545 1/20 0.38
USP30 Q70CQ3 1/20 0.37
CXCR3 P49682 1/20 0.37
CTSL P07711 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
SLC18A3 Q16572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039490 0.93 CTSK (0.54) CTSKCTSSALDH1A1PREPFAP
SCHEMBL4043775 0.92 CTSK (0.50) CTSKCTSSALDH1A1KMT2APREP
SCHEMBL4041463 0.92 CTSK (0.43) CTSKALDH1A1CHRNB2CHRNA7CHRNA4
SCHEMBL4041900 0.92 CTSK (0.54) CTSKCTSSALDH1A1PREPFAP
SCHEMBL4042674 0.92 CTSK (0.51) CTSKCTSSALDH1A1PREPFAP
SCHEMBL4045315 0.91 CTSK (0.53) CTSKCTSSALDH1A1RAB9APREP
SCHEMBL4040987 0.91 CTSK (0.65) CTSKCTSSALDH1A1RAB9APREP
SCHEMBL4046916 0.90 CTSK (0.65) CTSKCTSSALDH1A1CHRNB2CHRNA7
SCHEMBL4037336 0.90 CTSK (0.56) CTSKCTSSALDH1A1PREPFAP
SCHEMBL4037456 0.90 CTSK (0.51) CTSKCTSSALDH1A1CHRNB2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
WO-2009055128-A2 COMPOSITIONS FOR CHEMICAL AND BIOLOGICAL DEFENSE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-04-30 WO disclosed
WO-2009026348-A2 ANTIFUNGAL AGENTS FROM A STREPTOMYCETE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-02-26 WO disclosed
WO-2007092029-A2 CATALYTIC NANOPARTICLES FOR NERVE-AGENT DESTRUCTION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-08-16 WO disclosed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP disclosed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO disclosed